Payment overview · 2025
General Payments
$2,153.61
116 reported records · 32 companies
Healthcare provider profile · identity verified
James Randall Thomas, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · OWENSBORO, KY · NPI 1578566410
Verified facts
What the public records show
CMS Open Payments records show James Randall Thomas, MD received $2,153.61 in general payments during 2025 across 116 reported records.
Novartis Pharmaceuticals Corporation accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 56 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Bosulif, Kisqali, Venclexta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Venclexta by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Eliquis by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Venclexta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KISQALI as an associated drug or biological on 31637 records involving 7959 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Kisqali by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOSULIF as an associated drug or biological on 3017 records involving 2109 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Bosulif by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $352.69 | 16.4% | 24 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $204.66 | 9.5% | 12 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $168.23 | 7.8% | 9 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $164.01 | 7.6% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $157.54 | 7.3% | 10 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $139.61 | 6.5% | 8 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $85.15 | 4.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $67.86 | 3.1% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $63.01 | 2.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.69 | 2.7% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $56.39 | 2.6% | 3 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $53.26 | 2.5% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $53.26 | 2.5% | 3 | 2025 |
| Iovance Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $48.58 | 2.3% | 4 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $46.51 | 2.2% | 1 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.61 | 1.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $39.97 | 1.9% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $38.17 | 1.8% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $36.35 | 1.7% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.12 | 1.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.84 | 1.3% | 1 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $28.61 | 1.3% | 1 | 2025 |
| PROGENICS PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $23.75 | 1.1% | 1 | 2025 |
| Celltrion USA Inc. | Unresolved — no canonical attribution shown | $22.01 | 1.0% | 1 | 2025 |
| ACCORD HEALTHCARE, INC. | Unresolved — no canonical attribution shown | $21.95 | 1.0% | 1 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $20.39 | 0.9% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $18.29 | 0.8% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $18.20 | 0.8% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $17.27 | 0.8% | 1 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $16.79 | 0.8% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $14.05 | 0.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.79 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,053.66 | 115 |
| Education | $99.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $148.22 | 8 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $139.08 | 9 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | Astellas Pharma US Inc, PFIZER INC. | $130.32 | 8 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC., Sumitomo Pharma America, Inc. | $106.07 | 6 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $96.62 | 6 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological, Drug | Astellas Pharma US Inc, PFIZER INC. | $81.06 | 5 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $77.23 | 5 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $73.40 | 5 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $67.86 | 3 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $63.01 | 3 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $55.21 | 6 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $53.77 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Biological, Drug | ABBVIE INC., Genentech USA, Inc. | $53.68 | 3 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $53.26 | 3 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $53.13 | 3 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $49.83 | 3 | 2025 |
Source payment records
|
|||||
| Amtagvi Normalized: amtagvi |
Drug | Iovance Biotherapeutics, Inc. | $48.58 | 4 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $46.51 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $41.65 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $39.97 | 2 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $39.13 | 2 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $38.25 | 2 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $38.25 | 2 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $38.17 | 2 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $37.99 | 2 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $36.88 | 2 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $36.35 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $35.12 | 2 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $33.14 | 2 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $32.22 | 2 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $32.22 | 2 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $29.96 | 2 | 2025 |
Source payment records
|
|||||
| Tivdak Normalized: tivdak |
Drug | Genmab U.S., Inc. | $28.61 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| PYLARIFY Normalized: pylarify |
Drug | PROGENICS PHARMACEUTICALS, INC. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| REVUFORJ Normalized: revuforj |
Drug | Syndax Pharmaceuticals, Inc. | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| VEGZELMA Normalized: vegzelma |
Biological | Celltrion USA Inc. | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| Camcevi Normalized: camcevi |
Drug | ACCORD HEALTHCARE, INC. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| POTELIGEO Normalized: poteligeo |
Drug | KYOWA KIRIN, INC. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOSULIF bosulif |
2025 | Bosulif | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KISQALI kisqali |
2025 | Kisqali | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | KISQALI open payments reported associated product |
CMS Open Payments — General Payments 31637 supporting records · 7959 recipient NPIs · example record 1200004789 |
Kisqali · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | BOSULIF open payments reported associated product |
CMS Open Payments — General Payments 3017 supporting records · 2109 recipient NPIs · example record 1228795613 |
Bosulif · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 167 | 44 |
| Prednisone | Prednisone | 76 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 59 | 14 |
| Ondansetron Odt | Ondansetron | 56 | 16 |
| Tamoxifen Citrate | Tamoxifen Citrate | 55 | 13 |
| Promethazine Hcl | Promethazine Hcl | 51 | 25 |
| Letrozole | Letrozole | 48 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | 15 |
| Potassium Chloride | Potassium Chloride | 44 | suppressed |
| Kisqali | Ribociclib Succinate | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 37 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 14 |
| Levothyroxine Sodium | Levothyroxine Sodium | 34 | suppressed |
| Famotidine | Famotidine | 31 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 30 | 13 |
| Dexamethasone | Dexamethasone | 29 | 11 |
| Omeprazole | Omeprazole | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Eliquis | Apixaban | 26 | suppressed |
| Gabapentin | Gabapentin | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Revlimid | Lenalidomide | 24 | suppressed |
| Bosulif | Bosutinib | 20 | suppressed |
| Lenalidomide | Lenalidomide | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Hydroxyurea | Hydroxyurea | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Venclexta | Venetoclax | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tibsovo | Ivosidenib | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,153.61 · 116 records | Novartis Pharmaceuticals Corporation | ADCETRIS, Amtagvi, BESREMI, BOSULIF, BRUKINSA, CARVYKTI, Camcevi, DATROWAY, ELREXFIO, EPKINLY, ERLEADA, Enhertu, FRUZAQLA, Fabhalta, IBRANCE, ICLUSIG, IMBRUVICA, INLYTA, Itovebi, JAKAFI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LIBTAYO, LUTATHERA, MI CANCER SEEK, MONJUVI, NERLYNX, OJJAARA, ORGOVYX, Onivyde, Orserdu, PADCEV, PLUVICTO, POTELIGEO, PYLARIFY, Polivy, REBLOZYL, REVUFORJ, RYBREVANT, RYTELO, SARCLISA, SCEMBLIX, TAGRISSO, TALZENNA, TEVIMBRA, TUKYSA, Tecentriq, Tivdak, Trodelvy, ULTOMIRIS, VEGZELMA, VENCLEXTA, Vyloy, XTANDI, ZYNYZ | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Bosulif play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error